Viewing Study NCT00473993


Ignite Creation Date: 2025-12-25 @ 1:06 AM
Ignite Modification Date: 2026-01-07 @ 3:07 AM
Study NCT ID: NCT00473993
Status: COMPLETED
Last Update Posted: 2009-02-16
First Post: 2007-05-15
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland
Sponsor: Seidenberg, Arztpraxis A., M.D.
Organization:

Study Overview

Official Title: Hepatitis C Bei Opioidabhängigen in Der Praxis, Eine Querschnittsuntersuchung
Status: COMPLETED
Status Verified Date: 2007-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: HepCOP
Brief Summary: Hepatitis C viral infection is common among opioid addicts in Zurich, Switzerland. The majority undergoes a maintenance treatment with methadone, heroin or buprenorphine. While stabilized by an opioid maintenance treatment (OMT)chronic hepatitis C can be treated with pegylated interferon plus ribavirin. As not sufficiently known, the results are comparable to the results of the treatment of nonaddicts.

Our crossectional study investigates how many patients undergoing OMT are adequately investigated concerning hepatitis C. If not, why are they not adequately investigated and treated? Representative data are collected in the local clinics and medical practices involved in OMT in the Kanton of Zurich. The patients files are revised and the involved doctors are asked through a structured interview.
Detailed Description: www.seidenberg.ch/hepcop.pdf

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: